The National Health Commission and other five departments recently issued a document to include 12 diseases in the scope of treatment and management of childhood hematological diseases and malignant tumors, and encourage localities to include children with frequent occurrences in the region and strong public feedback on the basis of diseases determined by the state. Major diseases.
It is understood that these 12 diseases include glioma, medulloblastoma, craniopharyngioma, ependymoma, malignant germ cell tumor, nasopharyngeal carcinoma, thyroid cancer, pleuropulmonary blastoma, neurofibroma Disease, Langerhans cell histiocytosis, chronic active Epstein-Barr virus infection, and immune hemolytic anemia.
The notice requires that all localities should promptly adjust and improve designated hospitals and diagnosis and treatment cooperation groups according to the needs of new disease types of diagnosis and treatment and case registration information data, refine diagnosis and treatment specifications and clinical pathways, improve medical security policies, and complete case information registration, Full management and follow-up.
There are many types of hematological diseases and malignant tumors in children, which are difficult to treat. The diagnosis and treatment of some diseases involves multiple disciplines or medical institutions, resulting in long treatment cycles, high medical expenses, low reimbursement rates, and heavy family burdens. In 2019, the National Health Commission and other five departments included 10 major childhood hematological diseases and malignant tumors, including aplastic anemia, into the treatment management and guarantee system for the first time.
